Pulmonary complications of liver cirrhosis

1. D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int. 2018;12 (Suppl 1):34–43.

PMID: 28681347. https://doi.org/10.1007/s12072-017-9808-z

2. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24(5):861–80.

PMID: 15516683. https://doi.org/10.1183/09031936.04.00010904

3. Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome – a liver-induced lung vascular disorder. New Eng J Med. 2008;358(22):2378–87.

PMID: 18509123. https://doi.org/10.1056/NEJMra0707185

4. (Fluckinger M. Vorkommen von trommelschlagelformigen finger-endphalangen ohne chronische veriinderungen an den lungen oder am herzen. Wiener Medizinische Wochenschrift 1884;49:1457–58 (In German)).

5. Kennedy TC, Knudson RJ. Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest. 1977;72(2):305–9.

PMID: 891282. https://doi.org/10.1378/chest.72.3.305

6. Krowka MJ, Porayko MK, Plevak DJ, Pappas SC, Steers JL, Krom RA, Wiesner RH. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: Case reports and literature review. Mayo Clin Proc. 1997;72(1):44–53.

PMID: 9005286. https://doi.org/10.4065/72.1.44

7. Goldberg DS, Krok K, Batra S, Trotter JF, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: An analysis of the UNOS database. Gastroenterology. 2014;146(5):1256–65.e1.

PMID: 24412528. PMCID: PMC3992191. https://doi.org/10.1053/j.gastro.2014.01.005

8. Raevens S, Rogiers X, Geerts A, Verhelst X, Samuel U, van Rosmalen M et al. Outcome of liver transplantation for hepatopulmonary syndrome: A Eurotransplant experience. Eur Respir J. 2019;53(2):1801096.

PMID: 30487203. https://doi.org/10.1183/13993003.01096-2018

9. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MAE et al. International liver transplant society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100(7):1440–52.

PMID: 27326810. https://doi.org/10.1097/tp.0000000000001229

10. Cartin-Ceba R, Krowka MJ. Pulmonary complications of portal hypertension. Clin Liver Dis. 2019;23(4):683–711.

PMID: 31563218. https://doi.org/10.1016/j.cld.2019.06.003

11. Riegler JL, Lang KA, Johnson SP, Westerman JH. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology. 1995;109(3):978–83.

PMID: 7657128. https://doi.org/10.1016/0016-5085(95)90409-3

12. Corley DA, Scharshmidt B, Bass N, Somberg K, Gold W. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology. 1997;113(2):728–30.

PMID: 9247498. https://doi.org/10.1053/gast.1997.v113.agast971130728

13. Porres-Aguilar M, Altamirano JT, Torre-Delgadillo A, Charlton MR, Duarte-Rojo A. Portopulmonary hypertension and hepatopulmonary syndrome: A clinician-oriented overview. Eur Respir Rev. 2012;21(125):223–33.

PMID: 22941887. PMCID: PMC9487331. https://doi.org/10.1183/09059180.00007211

14. Lv Y, Fan D. Hepatopulmonary syndrome. Dig Dis Sci. 2015;60(7):1914–23.

PMID: 25732713. https://doi.org/10.1007/s10620-015-3593-0

15. Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE et al; Pulmonary Vascular Complications of Liver Disease Study Group. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008;135(4):1168–75.

PMID: 18644373. PMCID: PMC2824882. https://doi.org/10.1053/j.gastro.2008.06.038

16. Bommena S, Gerkin RD, Agarwal S, Raevens S, Glassberg MK, Fallon MB. Diagnosis of hepatopulmonary syndrome in a large integrated health system. Clin Gastroenterol Hepatol. 2021;19(11):2370–78.

PMID: 33007510. https://doi.org/10.1016/j.cgh.2020.09.050

17. Forde KA, Fallon MB, Krowka MJ, Sprys M, Goldberg DS, Krok KL et al.; Pulmonary Vascular Complications of Liver Disease 2 Study Group. Pulse oximetry is insensitive for detection of hepatopulmonary syndrome in patients evaluated for liver transplantation. Hepatology. 2019;69(1):270–81.

PMID: 30070715. PMCID: PMC6652183. https://doi.org/10.1002/hep.30139

18. Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: An analysis of cutoff values. Liver Transpl. 2013;19(6):602–10.

PMID: 23584902. https://doi.org/10.1002/Lt.23649

19. Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: The pulmonary vascular enigmas of liver disease. Clin Liver Dis (Hoboken). 2020;15(Suppl 1):S13–S24.

PMID: 32140210. PMCID: PMC7050952. https://doi.org/10.1002/cld.846

20. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991;100(2):520–28.

PMID: 1985048. https://doi.org/10.1016/0016-5085(91)90225-a

21. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg. 1997;3(5):494–500.

PMID: 9346791. https://doi.org/10.1002/Lt.500030503

22. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology. 2005;41(5):1122–29.

PMID: 15828054. https://doi.org/10.1002/hep.20658

23. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD. Portopulmonary hypertension: A report from the US-based REVEAL Registry. Chest. 2012;141(4):906–15.

PMID: 21778257. https://doi.org/10.1378/chest.11-0160

24. Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol. 2020;73(1):130–39.

PMID: 32145258. https://doi.org/10.1016/j.jhep.2020.02.021

25. Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): A multicentre, randomised, double-blind, placebocontrolled, phase 4 trial. Lancet Respir Med. 2019;7(7):594–604.

PMID: 31178422. https://doi.org/10.1016/S2213-2600(19)30091-8

26. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE et al. Predicting survival in patients with pulmonary arterial hypertension: The REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–37.

PMID: 30772387. https://doi.org/10.1016/j.chest.2019.02.004

27. Salvador LM, Loaiza CAQ, Padial LR, Barberá JA, López-Meseguer M, López-Reyes R et al.; REHAP Investigators. Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. Intern Med J. 2021;51(3):355–65.

PMID: 31943676. https://doi.org/10.1111/imj.14751

28. Banini BA, Alwatari Y, Stovall M, Ogden N, Gershman E, Shah RD et al. Multidisciplinary management of hepatic hydrothorax in 2020: An evidence-based review and guidance. Hepatology. 2020;72(5):1851–63.

PMID: 32585037. https://doi.org/10.1002/hep.31434

29. Morrow CS, Kantor M, Armen RN. Hepatic hydrothorax. Ann Intern Med. 1958;49(1):193–203.

PMID: 13545745. https://doi.org/10.7326/0003-4819-49-1-193

30. Lv Y, Han G, Fan D. Hepatic hydrothorax. Ann Hepatol. 2018;17(1):33–46.

PMID: 29311408. https://doi.org/10.5604/01.3001.0010.7533

31. O’Leary JG, Reddy KR, Tandon P, Biggins SW, Wong F, Kamath PS et al. Increased risk of ACLF and inpatient mortality in hospitalized patients with cirrhosis and hepatic hydrothorax. Dig Dis Sci. 2021;66(10):3612–18.

PMID: 33185787. PMCID: PMC11034783. https://doi.org/10.1007/s10620-020-06677-6

32. Garbuzenko DV, Arefyev NO. Hepatic hydrothorax: An update and review of the literature. World J Hepatol. 2017;9:1197–1204.

PMID: 29152039. PMCID: PMC5680207. https://doi.org/10.4254/wjh.v9.i31.1197

33. Gurung P, Goldblatt M, Huggins JT, Doelken P, Nietert PJ, Sahn SA. Pleural fluid analysis and radiographic, sonographic, and echocardiographic characteristics of hepatic hydrothorax. Chest. 2011;140(2):448–53.

PMID: 21273292. PMCID: PMC3148794. https://doi.org/.1378/chest.10-2134

34. Singh A, Bajwa A, Shujaat A. Evidence-based review of the management of hepatic hydrothorax. Respiration. 2013;86(2):155–73.

PMID: 23571767. https://doi.org/10.1159/000346996

35. Covington MF, Choudhary G, Avery RJ, Kuo PH. Pitfalls in the performance and interpretation of scintigraphic imaging for pleuroperitoneal shunt. Clin Nucl Med. 2016;41(11):858–61.

PMID: 27488430. https://doi.org/10.1097/RLU.0000000000001326

36. Helmy N, Akl Y, Kaddah S, El Hafiz HA, El Makhzangy H. A case series: Egyptian experience in using chemical pleurodesis as an alternative management in refractory hepatic hydrothorax. Arch Med Sci. 2010;6(3):336–42.

PMID: 2231768. PMCID: PMC3282509. https://doi.org/10.5114/aoms.2010.14252

37. Ferrante D, Arguedas MR, Cerfolio RJ, Collins BG, van Leeuwen DJ. Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. Am J Gastroenterol. 2002;97(12):3172–75.

PMID: 12492206. https://doi.org/10.1111/j.1572-0241.2002.07126.x

38. Lee WJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI et al. Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis. Korean J Hepatol. 2011;17(4):292–98.

PMID: 22310793. PMCID: PMC3304667. https://doi.org/10.3350/kjhep.2011.17.4.292

39. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rössle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: Long-term results in 40 patients. Eur J Gastroenterol Hepatol. 2001;13(5):529–34.

PMID: 11396532. https://doi.org/10.1097/00042737-200105000-00011

40. Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology. 1997;25(6):1366–69.

PMID: 9185754. https://doi.org/10.1002/hep.510250611

41. Jeffries MA, Kazanjian S, Wilson M, Punch J, Fontana RJ. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg. 1998;4(5):416–23.

PMID: 9724480. https://doi.org/10.1002/Lt.500040506

42. Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, Boyer TD. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology. 2000;118(1):138–44.

PMID: 10611162. https://doi.org/10.1016/s0016-5085(00)70422-7

43. Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2010;105(3):635–41.

PMID: 19904245. https://doi.org/10.1038/ajg.2009.634

44. Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol. 2002;13(4):385–90.

PMID: 11932369. https://doi.org/10.1016/s1051-0443(07)61741-2

45. Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, Figueras J. Liver transplantation in patients with hepatic hydrothorax. Transpl Int. 2005;18(6):672–75.

PMID: 15910292. https://doi.org/10.1111/j.1432-2277.2005.00116.x

46. Serste T, Moreno C, Francoz C, Razek WA, Paugham C, Belghitti J et al. The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. Eur J Gastroenterol Hepatol. 2010;22(2):207–12.

PMID: 19779352. https://doi.org/10.1097/MEG.0b013e3283311140

47. Abbasi A, Bhutto AR, Alam MT, Aurangzaib M, Masroor M. Frequency of hepatic hydrothorax and its association with Child Pugh class in liver cirrhosis patients. J Coll Physicians Surg Pak. 2016;26(7):566–69. PMID: 27504545.

48. Deleuran T, Watson H, Vilstrup H, Jepsen P. Risk factors for hepatic hydrothorax in cirrhosis patients with ascites – a clinical cohort study. Dig Dis Sci. 2022;67(7):3395–3401.

PMID: 34191185. https://doi.org/10.1007/s10620-021-07134-8

49. Matei D, Craciun R, Crisan D, Procopet B, Mocan T, Pasca S et al. Hepatic hydrothorax an independent decompensating event associated with long-term mortality in patients with cirrhosis. J Clin Med. 2021;10(16):3688.

PMID: 34441984. PMCID: PMC8396982. https://doi.org/10.3390/jcm10163688

50. Hung T-H, Tseng C-W, Tsai C-C, Tsai C-C, Tseng K-C, Hsieh Y-H. The long-term outcomes of cirrhotic patients with pleural effusion. Saudi J Gastroenterol. 2018;24(1):46–51.

PMID: 29451184. PMCID: PMC5848324. https://doi.org/10.4103/sjg.SJG_336_17